^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Thymoma |
| Regimen: | CAP (cisplatin + cyclophosphamide + doxorubicin hydrochloride) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Thymoma: FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS...Preferred (Other Recommended for Thymic Carcinoma)...CAP...Cisplatin 50 mg/m2 IV day 1...Doxorubicin 50 mg/m2 IV day 1...Cyclophosphamide 500 mg/m2 IV day 1...Administered every 3 weeks…
